Companion Diagnostic Technologies Market by Indications (Oncology, Central Nervous System, Cardiovascular) and Technology (Immunohistochemistry, Molecular Diagnostics) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

Companion Diagnostic Technologies Market Overview: 2020

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020.

The global companion diagnostic technologies market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drugs and corresponding diagnosis. However, cost associated with developing drugs could impede the growth of this companion diagnostics technologies market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technologies Market Analysis

Companion diagnostics technologies market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion diagnostics technologies market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions. 

Competitive Analysis

A study of some of the key players has shown that the majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is an emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porter's five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage. 

Reason for doing the study 

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.

KEY BENEFITS

• In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
• Analysis of the market by geography would help in making region specific plans
• Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
• Porters five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
• Top factors impacting the market would help in making decisions for business development 

KEY DELIVERABLES

MARKET BY INDICATIONS

• Oncology 
• Cardiovascular 
• Central Nervous System 
• Auto immune & Inflammation 
• Virology
• Others

MARKET BY TECHNOLOGY 

• Immunohistochemistry
• Molecular diagnostics
• In situ Hybridization
• FISH
• CISH
• Real time PCR
• Gene Sequencing 

MARKET BY GEOGRAPHY 

• North America
• Europe
• Asia Pacific 
• LAMEA

CHAPTER 1. INTRODUCTION

1.1 Report description

1.2 Key market segments

1.3 Research methodology

1.3.1 Secondary research

1.3.2 Primary research

1.3.3 Analyst tools and models

CHAPTER 2. EXECUTIVE SUMMARY

CHAPTER 3. MARKET OVERVIEW 

3.1 Market Definition and Scope

3.2 Companion Diagnostics for Metabolic Diseases

3.3 Novel trends and technologies in companion diagnostics assay development

3.4 Companion diagnostics as a new trend in personalized medicine

3.5 Biomarkers market as basis for the companion diagnostics industry

3.6 Key Findings

3.6.1 Top Factors Impacting The Companion Diagnostic Market

3.6.2 Top Winning Strategies

3.7 Porter’s five forces analysis

3.7.1 High switching cost leads to higher bargaining power of suppliers

3.7.2 Highly differentiated products leads to lower bargaining power of buyers

3.7.3 Specificity of diagnostics lowers the threat of substitutes

3.7.4 Higher capital investment leads to lesser threat of entrants

3.7.5 Few competitors leads to low competition among players

3.8 Government Regulations

3.8.1 FDA regulations

3.8.2 Europe

3.8.3 Japan

3.8.4 China

3.9 Value Chain Analysis

3.10 Case Study

3.11 Drivers

3.11.1 Increased popularity of Personalized medicine

3.11.2 Increasing cases of adverse drug reactions(ADRs)

3.11.3 Increase in the Discovery of Biomarkers as drug targets.

3.11.4 Rising success of co-development drugs speedily approved by the FDA

3.11.5 Technological advancements

3.11.6 Rising incidences of diseases

3.12 Restraints

3.12.1 High Cost in research and development of drugs

3.12.1.1 Economic and scientific obstacles

3.12.2 Opportunities

3.12.2.1 Opportunities in treatment of neurodegenerative diseases

3.12.2.2 Companion diagnostics for hereditary mutations

CHAPTER 4. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS

4.1 Oncology

4.1.1 Companion diagnostics oncology market by geography,

4.1.2 Breast Cancer

4.1.2.1 companion diagnostics breast cancer market by geography

4.1.3 Lung Cancer

4.1.3.1 companion diagnostics lung cancer market by geography

4.1.4 Colorectal Cancer

4.1.4.1 companion diagnostics Colorectal Cancer market by geography

4.1.5 Gastric cancer

 4.1.5.1 companion diagnostics Gastric Cancer market by geography

4.1.6 Melanomas

4.1.6.1 companion diagnostics Melanoma market by geography

4.2 Inflammation and Autoimmune diseases

4.2.1 Companion diagnostics inflammation market by geography

4.3 Companion diagnostics in cardiovascular diseases

4.3.1 Companion diagnostics tests for warfarin

4.3.2 Companion diagnostics cardiovascular market by geography

4.4 Companion diagnostics in CNS disorders

4.4.1 Companion diagnostics CNS market by geography

4.5 Companion diagnostics tests in virology diseases

4.5.1 Companion diagnostics virology market by geography

4.6 Others

4.6.1 Companion diagnostics others market by geography

CHAPTER 5. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

5.1 Companion diagnostics technology market by geography

5.2 Immunohistochemistry

5.2.1 Companion diagnostics Immmunohistochemistry market by geography

5.3 Molecular Diagnostics

5.3.1 Companion diagnostics molecular diagnostics market by types

5.3.2 Companion diagnostics Molecular Diagnostics market by geography

5.3.3 In-situ Hybridization    

5.3.3.1 Fluorescent In-situ Hybridization(FISH)

5.3.3.2 CISH (Chromogenic In-Situ Hybridization)

5.3.3.3 Companion diagnostics In situ Hybridization market by geography

5.3.4 Real Time PCR

5.3.4.1 Companion diagnostics RT PCR market by geography

5.3.5 Gene Sequencing

5.3.5.1 Companion diagnostics Sequencing market by geography

5.3.6 Others

5.3.6.1 Others molecular companion diagnostics market by geography

CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY

6.1 North America

6.1.1 Companion diagnostics North America market by indication

6.2 Europe

6.2.1 Companion diagnostics Europe market by indication

6.3 Asia Pacific

6.3.1 Companion diagnostics Asia Pacific market by indication

6.4 RoW

6.4.1 Companion diagnostics RoW market by indication

CHAPTER 7. COMPANY PROFILES

7.1 Qiagen

7.1.1 Company Overview:

7.1.2 Company Snapshot

7.1.3 Business Performance

7.1.4 Strategy move and development

7.1.4.1    Principal strategies Collaborations

7.1.4.2    Secondary Strategies Approval

7.1.5 SWOT Analysis of Qiagen

7.2 Dako (Agilent Technologies)

7.2.1 Company Overview

7.2.2 Company Snapshot

7.2.3 Business Performance

7.2.4 Strategic Moves and Development

7.2.4.1  Principal strategies Collaboration

7.2.4.2  Secondary Strategies Approval

7.2.5 SWOT Analysis of Dako

7.3 Roche

7.3.1 Company overview

7.3.2 Company Snapshot

7.3.3 Business Performance

7.3.4 Strategies move and development

7.3.5 SWOT analysis of Roche

7.4 Abbott Laboratories, Inc.

7.4.1 Company Overview

7.4.2 Company Snapshot

7.4.3 Business Performance

7.4.4 Principal Strategies Collaboration

7.4.5 SWOT Analysis of Abbot

7.5 BioMerieux 

7.5.1 Company Overview

7.5.2 Company snapshot:

7.5.3 Business Performance

7.5.4 Strategies and development Approval

7.5.5 SWOT Analysis of BioMerieux, 

7.6 Ventana Medical Systems

7.6.1 Company Profile

7.6.2 Company Snapshot

7.6.3 Business Performance

7.6.4 Strategies and development  

7.6.5 SWOT Analysis of Ventana

7.7 Myriad Genetics, Inc.

7.7.1 Company Overview

7.7.2 Company snapshot

7.7.3 Business Performance

7.7.4 Strategies  and  development

7.7.5 SWOT Analysis of Myraid

7.8 Resonance Health Ltd

7.8.1 Company Overview

7.8.2 Company Snapshot

7.8.3 Strategies move and development

7.8.4 SWOT Analysis of Ferriscan

7.9 Leica Microsystems

7.9.1 Company overview

7.9.2 Company Snapshot

7.9.3 Strategies move and Development

7.9.4 SWOT Analysis of Leica Microsystems

7.10 Life Technologies

7.10.1 Company Overview

7.10.2 Company Snapshot

7.10.3 Business performance

7.10.4 Strategies move and Development

7.10.5 SWOT Analysis of Life Technologies

LIST OF TABLES

TABLE 1    GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION)
TABLE 2    COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 3    GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION)
TABLE 4    COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 5    COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 6    COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 7    COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 8    COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 9    COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 10 COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 11 COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 12 COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 13 COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 14 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 15 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION)
TABLE 16 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 17 COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 18 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION)
TABLE 19 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 20 COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 21 COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 22 COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 24 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25 COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
TABLE 26 COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
TABLE 27 COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
TABLE 28 COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
TABLE 29 QIAGEN SNAPSHOT
TABLE 30 DAKO COMPANY SNAPSHOT
TABLE 31 ROCHE COMPANY SNAPSHOT
TABLE 32 ABBOTT COMPANY SNAPSHOT
TABLE 33 BIOMERIEUX COMPANY SNAPSHOT
TABLE 34 VENTANA COMPANY SNAPSHOT
TABLE 35 MYRIAD COMPANY SNAPSHOT
TABLE 36 RESONANCE COMPANY SNAPSHOT
TABLE 37 LEICA COMPANY SNAPSHOT
TABLE 38 LIFE TECHNOLOGIES COMPANY SNAPSHOT

LIST OF FIGURES

FIG.1 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
FIG.2 EFFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
FIG.3 LIST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
FIG.4 TOP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
FIG.5 TOP WINNING STRATEGIES
FIG.6 VALUE CHAIN ANALYSIS
FIG.7 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG.8 FINANCIAL REVENUES BY GEOGRAPHY(2013)
FIG.9 SWOT ANALYSIS OF QIAGEN
FIG.10 FINANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
FIG.11 SWOT ANALYSIS OF DAKO
FIG.12 FINANCIAL REVENUE OF DAKO, BY SEGMENT
FIG.13 FINANCIAL REVENUE OF DAKO, BY GEOGRAPHY
FIG.14 SWOT ANALYSIS OF ROCHE
FIG.15 REVENUE BY BUSINESS SEGMENTS
FIG.16 REVENUE BY GEOGRAPHY
FIG.17 SWOT ANALYSIS OF ABBOTT
FIG.18 FINANCIAL REVENUES BY GEOGRAPHY
FIG.19 FINANCIAL REVENUES BY TECHNOLOGY
FIG.20 SWOT ANALYSIS OF BIOMERIEUX
FIG.21 SWOT ANALYSIS OF VENTANA
FIG.22 REVENUE BY DIAGNOSTIC TYPE
FIG.23 SWOT ANALYSIS OF MYRAID
FIG.24 SWOT ANALYSIS OF FERRISCAN
FIG.25 SWOT ANALYSIS OF LEICA MICROSYSTEMS
FIG.26 REVENUE BY END MARKETS
FIG.27 SWOT ANALYSIS OF LIFE TECHNOLOGIES